Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein ESX1 (ESX1) is a dual-function 65 kDa protein primarily expressed in testis and placental tissues. Following proteolytic cleavage, it yields an N-terminal fragment (containing a paired-like homeodomain, localized to the nucleus and acting as a transcriptional repressor) and a C-terminal fragment (proline-rich, cytoplasmic). ESX1 regulates gene expression by binding sequence-specifically to DNA (5'-TAATGTTATTA-3'), notably inhibiting expression of genes such as KRAS. It also plays a critical role in cell cycle regulation by inhibiting the degradation of polyubiquitinated cyclin A and B1, causing cell cycle arrest in early M phase. ESX1 is important for normal spermatogenesis in males and for placental development. Mutations or alterations in this gene have been implicated in male infertility and certain tumors such as adamantinomatous craniopharyngioma[1][2][3][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein ESX1 (ESX1).